{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:19:30Z","timestamp":1780514370952,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jtct.2026.01.023","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:25:35Z","timestamp":1769012735000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Pretransplant Blinatumomab on Post-Transplant Outcomes in B Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-433X","authenticated-orcid":false,"given":"Sergio","family":"Rodriguez-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2305-9638","authenticated-orcid":false,"given":"Fausto Alfredo","family":"Rios-Olais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8316-7759","authenticated-orcid":false,"given":"Rouhi","family":"Fazelzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-0113","authenticated-orcid":false,"given":"Ivan","family":"Pasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.jtct.2026.01.023_bib0001","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.023_bib0002","article-title":"Expert recommendations for the diagnosis, treatment, and management of adult B-cell acute lymphoblastic leukemia in Latin America","volume":"9","author":"Basquiera","year":"2023","journal-title":"JCO Glob Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.01.023_bib0003","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ajh.24629","article-title":"Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission","volume":"92","author":"Pemmaraju","year":"2017","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2026.01.023_bib0004","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","article-title":"Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients","volume":"107","author":"Saygin","year":"2022","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.jtct.2026.01.023_bib0005","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jtct.2026.01.023_bib0006","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.01.023_bib0007","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.023_bib0008","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.01.023_bib0009","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/blood-2024-209408","article-title":"Clinical impact of pretransplant blinatumomab in predominantly Hispanic adults with B-Cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"144","author":"Ginosyan","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.01.023_bib0010","doi-asserted-by":"crossref","first-page":"520.e1","DOI":"10.1016\/j.jtct.2024.03.004","article-title":"Pretransplant Blinatumomab improves outcomes in B cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation","volume":"30","author":"Sayyed","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"ED000142","key":"10.1016\/j.jtct.2026.01.023_bib0011","first-page":"1","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"n71","key":"10.1016\/j.jtct.2026.01.023_bib0012","first-page":"1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"The BMJ"},{"issue":"n160","key":"10.1016\/j.jtct.2026.01.023_bib0013","first-page":"1","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jtct.2026.01.023_bib0014","doi-asserted-by":"crossref","first-page":"e0263661","DOI":"10.1371\/journal.pone.0263661","article-title":"Methodology to standardize heterogeneous statistical data presentations for combining time-to-event oncologic outcomes","volume":"17","author":"Hebert","year":"2022","journal-title":"PLoS One"},{"issue":"I4898","key":"10.1016\/j.jtct.2026.01.023_bib0015","first-page":"1","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"I4919","key":"10.1016\/j.jtct.2026.01.023_bib0016","first-page":"1","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Online)"},{"key":"10.1016\/j.jtct.2026.01.023_bib0017","unstructured":"Sterne J, Brandt Mathur M, Elbers R, et al. Risk Of bias in non-randomized studies \u2013 of interventions, version 2 (ROBINS-I V2). 2025."},{"issue":"1","key":"10.1016\/j.jtct.2026.01.023_bib0018","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (ROBVis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jtct.2026.01.023_bib0019","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","first-page":"243","article-title":"Analysing data and undertaking meta-analyses","author":"Deeks","year":"2008"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.023_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12874-021-01310-0","article-title":"Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study","volume":"21","author":"Geissb\u00fchler","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.023_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"Inthout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"10.1016\/j.jtct.2026.01.023_bib0022","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses testing for heterogeneity","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jtct.2026.01.023_bib0023","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.01.023_bib0024","doi-asserted-by":"crossref","first-page":"165.e1","DOI":"10.1016\/j.jtct.2020.10.015","article-title":"Impact of novel targeted therapies and cytogenetic risk groups on outcome after allogeneic transplantation for adult ALL","volume":"27","author":"Abdel Rahman","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.01.023_bib0025","doi-asserted-by":"crossref","first-page":"182.e1","DOI":"10.1016\/j.jtct.2022.12.018","article-title":"Allogeneic Blood or Marrow transplantation with high-dose post-transplantation cyclophosphamide for acute lymphoblastic leukemia in patients age \u226555 Years","volume":"29","author":"Webster","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.023_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01127-2","article-title":"Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease","volume":"14","author":"Lu","year":"2024","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.023_bib0027","doi-asserted-by":"crossref","first-page":"554","DOI":"10.21147\/j.issn.1000-9604.2025.04.08","article-title":"Outcomes of adult patients with B-cell acute lymphoblastic leukemia with or without blinatumomab as bridging therapy prior to allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Huang","year":"2025","journal-title":"Chin J Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.01.023_bib0028","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1182\/blood-2024-205953","article-title":"Efficacy and safety of blinatumomab versus chemotherapy in treating first-relapse B-ALL: a meta-analysis of randomized controlled trials","volume":"144","author":"Qandil","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.01.023_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2025.05.004","article-title":"Blinatumomab versus chemotherapy for post-induction consolidation in first relapse of B-cell acute lymphoblastic leukemia: a systematic review and meta-analysis of randomized clinical trials","author":"da Silva","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.jtct.2026.01.023_bib0030","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/CM9.0000000000001402","article-title":"A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.023_bib0031","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","article-title":"Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis","volume":"18","author":"Shen","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2026.01.023_bib0032","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.2023023699","article-title":"How I use next-generation sequencing\u2013MRD to plan approach and prevent relapse after HCT for children and adults with ALL","volume":"144","author":"Muffly","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.01.023_bib0033","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/bloodadvances.2024014781","article-title":"PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation","volume":"9","author":"Desai","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.01.023_bib0034","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1111\/bjh.70124","article-title":"A decade of experience using <scp>ATG<\/scp>and <scp>PTCy<\/scp>for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation","volume":"207","author":"Desai","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.023_bib0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-024-01092-w","article-title":"Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia\/lymphoma following allogeneic hematopoietic cell transplantation","volume":"14","author":"Huang","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jtct.2026.01.023_bib0036","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:08:36Z","timestamp":1776856116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726000588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S2666636726000588"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Pretransplant Blinatumomab on Post-Transplant Outcomes in B Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}